CN Patent

CN105213392A — 泊马度胺在制备减轻多发性硬化症的药物中的应用

Assigned to Zhejiang University ZJU · Expires 2016-01-06 · 10y expired

What this patent protects

本发明涉及一种用于治疗多发性硬化症的药物，它是沙利度胺的衍生物泊马度胺，目前临床上主要用于复发性难治性多发性骨髓瘤。非临床研究证明，泊马度胺对M.Tuberculosis(4mg/ml)、MOG 35-55？ (2mg/ml)、Pertussis？toxin（200ng？per？mouse）所诱导的炎性脱髓鞘的EAE小鼠有显著的保护效果，能应用于多发性硬化症的治疗。

USPTO Abstract

本发明涉及一种用于治疗多发性硬化症的药物，它是沙利度胺的衍生物泊马度胺，目前临床上主要用于复发性难治性多发性骨髓瘤。非临床研究证明，泊马度胺对M.Tuberculosis(4mg/ml)、MOG 35-55？ (2mg/ml)、Pertussis？toxin（200ng？per？mouse）所诱导的炎性脱髓鞘的EAE小鼠有显著的保护效果，能应用于多发性硬化症的治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN105213392A
Jurisdiction
CN
Classification
—
Expires
2016-01-06
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang University ZJU
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.